NCT04119024 2026-03-17Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsStanford UniversityPhase 1 Recruiting18 enrolled
NCT01659151 2026-02-20Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed17 enrolled 11 charts